Shorter radiation plus chemo for glioblastoma patients under 70
Part of Cancer clinical trials.
This trial tests a shorter course of radiation therapy combined with the chemotherapy drug temozolomide for people with glioblastoma. It aims to see if this approach works as well as standard treatment while being more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a first-time diagnosis of glioblastoma, a type of brain cancer.
- You must be between 18 and 70 years old.
- You must be able to take care of most daily activities (score of 70% or higher on the Karnofsky scale).
- You must agree to take part in the study.
- You have not had radiation to your head before.
- Your tumor must not be multicentric (multiple separate tumors in the brain).
- You must be able to have temozolomide chemotherapy.
- You must be able to have an MRI scan (no metal implants or other contraindications).
- If you could become pregnant, you must agree to a pregnancy test and use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a more focused, stronger dose of radiation can improve outcomes for people 65 and older with newly diagnosed glioblastoma. It compares this approach to standard radiation to see if it's safe and effective.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests a type of radiation therapy that uses a smaller, more focused area on the brain after surgery for glioblastoma. The goal is to see if this approach can reduce side effects while still controlling the tumor.
This trial tests a shorter, more intense course of radiation therapy (hypofractionated radiotherapy) for people with newly diagnosed glioblastoma who have had surgery. The goal is to see if this approach is safe and works well for treating the tumor.
This study compares a standard radiation schedule versus a shorter, higher-dose radiation schedule, both with the chemotherapy medicine temozolomide, in older adults with newly diagnosed glioblastoma. It aims to see which approach works better and is practical for people age 70 and older.
This trial tests a shorter course of radiation (hypofractionated RT) for people with a specific type of aggressive brain tumor (GBM) that is not suitable for surgery. It aims to see if this shorter treatment can be effective with fewer side effects.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.